Pneumatic displacement and intravitreal bevacizumab: a new approach for management of submacular hemorrhage in choroidal neovascular membrane.
Indian J Ophthalmol
;
2009 Mar-Apr; 57(2): 155-7
Article
Dans Anglais
| IMSEAR
| ID: sea-71385
ABSTRACT
Choroidal neovascular membrane (CNVM) is one of the most common causes of submacular hemorrhage (SMH). Conventional treatment involves management of the SMH with pneumatic displacement with or without tissue plasminogen activator (TPA) followed by intravitreal injection of bevacizumab in a second sitting. We decided to assess the efficacy of treating SMH secondary to CNVM with pneumatic displacement using sulphur hexafluoride (SF6) gas and intravitreal bevacizumab. Four patients with SMH secondary to CNVM were included in this study. Intravitreal bevacizumab, 0.05 ml, along with 0.5 ml of SF6 was injected through the pars plana into the vitreous cavity. Postoperative best corrected visual acuity improved in all eyes with complete or partial displacement of SMH out of the foveal area.
Texte intégral:
Disponible
Indice:
IMSEAR (Asie du Sud-Est)
Sujet Principal:
Pression
/
Hexafluorure de soufre
/
Corps vitré
/
Sujet âgé
/
Femelle
/
Humains
/
Mâle
/
Hémorragie de la rétine
/
Angiographie fluorescéinique
/
Acuité visuelle
langue:
Anglais
Texte intégral:
Indian J Ophthalmol
Année:
2009
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS